Lack of Efficacy Ends Trial Evaluating Janssen’s HIV Vaccine Candidate
The decision to discontinue the study was made based on an analysis from an independent data and safety monitoring board.
Diagnosis & Disease Information
Discontinuation of Several HIV Medications Reported to FDA
The HIV medications are all manufactured by ViiV Healthcare, a GlaxoSmithKline.
Clinicians Address the Resurgence of Syphilis in the United States
Syphilis diagnoses have continued to accelerate for the past few years due to COVID-19 pandemic-related restrictions at sexual health clinics.
New Trogarzo Administration Method Cuts Maintenance Dose Time for HIV Patients
The approval was based on data from the phase 3 TMB-302 trial that evaluated Trogarzo 800mg administered via IV push once every 2 weeks.
Investigation Into Counterfeit HIV Med Spurs Legal Action
The legal action follows an investigation that identified counterfeit products being sold by distributors not authorized to sell Janssen’s medicines.
Diagnostic Accuracy of Point-of-Care HIV Viral Load Tests vs Laboratory-Based Assays
In this meta-analysis, researched compared the diagnostic accuracy point-of-care HIV RNA viral load tests with laboratory-based assays to detect antiretroviral therapy treatment failure in patients with HIV infection.
Cabenuva Approval Expanded to Include Adolescents With HIV
The expanded approval was supported by data from studies in the adult population and by data from an interim analysis of the phase 1/2 MOCHA study.
Combine and Conquer: A Treatment Strategy to Combat Drug-Use Associated Infections
Sandra Springer, MD, and Laura Marks, MD, PhD, highlight the need for a combined treatment approach for patients with drug-use associated infections.
Profound Disparity in HIV Diagnoses Among Black Individuals Observed in 2018
In this study, researchers assessed the rate of HIV diagnoses in Black individuals in the United States, particularly among those living in communities with increased social vulnerability.
Cabenuva Approval Expanded to Include Every 2 Month Dosing Option for HIV
Cabenuva is a 2-drug co-packaged product that combines cabotegravir, an HIV integrase strand transfer inhibitor, and rilpivirine, an HIV non-nucleoside reverse transcriptase inhibitor.
- Loading...
Loading...
Next post in News
Loading... 
Loading...